In lieu of hard M&A news, one group of analysts crunches the numbers around a $40B Seagen buy
Some of the analysts at SVB Securities have been playing with the numbers that might set the stage for Merck $MRK — or some other Big Pharma — to come in and make a buyout of Seagen $SGEN work. And while it’s all pure speculation, it does help provide a rough outline for what a deal could look like in H2 as investors wait with bated breath for the bottom of a miserable public biotech market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.